No single ticker was named. Biotech ETFs are one way for retail investors to get exposure. Not a recommendation.
US clinical trial reform to counter China
The guest argued that the US must replace FDA permission-based first-in-human trial approvals with an IRB-based notification system to lower costs and stop losing drug development to China.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day — no card required.